Maxim Group Issues a Buy Rating on VolitionRX (VNRX)

In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to VolitionRX (VNRXResearch Report), with a price target of $8.00. The company’s shares closed last Friday at $3.26.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 23.0% and a 46.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and Interpace Diagnostics Group.

VolitionRX has an analyst consensus of Strong Buy, with a price target consensus of $7.67, a 131.0% upside from current levels. In a report issued on October 20, Oppenheimer also maintained a Buy rating on the stock with a $7.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.12 and a one-year low of $2.22. Currently, VolitionRX has an average volume of 188.5K.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is neutral on the stock. Most recently, in August 2020, Guy Archibald Innes, a Director at VNRX bought 30,000 shares for a total of $82,500.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Austin, TX.